Figure 3. Overall Survival (OS) in Prespecified Patient Subgroups Defined by Baseline Clinical Characteristics.

A, Forest plot of unstratified hazard ratios (HRs) for death in the analysis of treatment effect in prespecified patient subgroups according to baseline characteristics. B, Exploratory post hoc analyses of the number of events, median OS, and Kaplan-Meier curves for OS in prespecified patient subgroups treated with nivolumab. C, Exploratory post hoc analyses for bevacizumab. Subgroups include patients with methylated tumors who did not receive corticosteroids at baseline, patients with methylated tumors who received corticosteroids at baseline, patients with unmethylated tumors who did not receive corticosteroids at baseline, and patients with unmethylated tumors who received corticosteroids at baseline. Symbols indicate censored observations; HRs and CIs were estimated using a Cox proportional hazards model.